IL17A and metabolic dysfunction-associated steatotic liver disease: Overexpression of miR-26a improves NAFLD and reduces IL-17 expression by partially reducing IL-6 expression, indicating the immunomodulatory effects of the miR-26a-IL-6-IL-17 axis in the pathological process of NAFLD.